To evaluate the effect of CD133 + cells (endothelial progenitor cells) on the hypoxia-induced suppression of axonal growth of cortical neurons and the destruction of blood vessels (endothelial cells), we used anterograde axonal tracing and immunofluorescence in organ co-cultures of the cortex and the spinal cord from 3-day-old neonatal rats. CD133
CD133
+ cells from human umbilical cord blood reduce cortical damage and promote axonal growth in neonatal rat organ co-cultures exposed to hypoxia + cells (endothelial progenitor cells) on the hypoxia-induced suppression of axonal growth of cortical neurons and the destruction of blood vessels (endothelial cells), we used anterograde axonal tracing and immunofluorescence in organ co-cultures of the cortex and the spinal cord from 3-day-old neonatal rats. CD133
+ cells prepared from human umbilical cord blood were added to the organ co-cultures after hypoxic insult, and axonal growth, vascular damage and apoptosis were evaluated. Anterograde axonal tracing with 1,1 -dioctadecyl-3,3,3 ,3 -tetramethylindocarbocyanine perchlorate was used to analyze axonal projections from the cortex to the spinal cord. Immunolabeling cocultured tissues of the cortex and the spinal cord were used to investigate the effect of CD133 + cells on the survival of blood vessels and apoptosis in the brain cortex. Hypoxia remarkably suppressed axonal growth in organ co-cultures of the cortex and the spinal cord, and this suppression was significantly restored by the addition of CD133 + cells. CD133 + cells also reduced the hypoxia-induced destruction of the cortical blood vessels and apoptosis. CD133 + cells had protective effects on hypoxia-induced injury of neurons and blood vessels of the brain cortex in vitro. These results suggest that CD133 + cell transplantation may be a possible therapeutic intervention for perinatal hypoxia-induced brain injury.
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Introduction
Hypoxic-ischemic encephalopathy (HIE) is a major cause of acute mortality and neurological complications in the newborn. However, its pathogenesis has not been fully elucidated. This type of perinatal injury results in motor disorders accompanied by other functional disturbances (Volpe, 2001) . The cerebral cortex is one of the regions in which hypoxic damage is primarily observed (Grafe, 1994; Rice et al., 1981; Stadlin et al., 2003) . Although many interventions for perinatal hypoxia-induced brain injury including HIE have been attempted, few have become established therapies. Therefore, the development of new strategies for treating perinatal hypoxia-induced brain injury is urgently needed.
In recent years stem cell therapies have been reported in several fields of medicine. Endothelial progenitor cells (EPC) are one of the
Abbreviations:
HIE, hypoxic-ischemic encephalopathy; EPC, endothelial progenitor cell; PBS, phosphate-buffered saline; DiI, 1,1 -dioctadecyl-3,3,3 ,3 -tetramethylindocarbocyanine perchlorate; hMit, human mitochondria; IB4, isolectin B4; DAPI, 4 ,6 -diamidino-2-phenylindole.
* Corresponding author. Tel.: +81 82 257 5262.
E-mail addresses: yoshkudo@hiroshima-u.ac.jp, takyoubun@hiroshima-u.ac.jp (Y. Kudo).
major stem/progenitor cell subsets with the potential for repairing vascular injury. EPCs from adult human peripheral blood were initially described by Asahara et al. (1997) . CD133 is a hematopoietic stem cell marker which is expressed on EPCs, but not on mature vascular endothelial cells (Yin et al., 1997) . EPCs are involved in promoting neovascularization and also have the capacity to protect and repair ischemic lesions (Asahara et al., 1997; van Velthoven et al., 2009) . Since these functions are central to rescuing ischemic tissue, these EPCs have been the focus of regenerative medicine for ischemia. More recently, Murohara et al. (2000) reported that EPCs derived from umbilical cord blood have a higher regenerative potential than adult bone marrow-derived EPCs. Since umbilical cord blood can be easily obtained without harm to either mother or infant, and is therefore a readily available source of cells for autotransplantation, EPCs from umbilical cord blood have an additional advantage for use as a therapy for infants. Moreover, a recent report has suggested that the transplantation of umbilical cord-derived EPCs improved ischemic brain damage and promoted neurogenesis in a model of adult stroke in mice (Taguchi et al., 2004) . Therefore, we speculated that the transplantation of CD133 + cells, as a EPCs containing fraction, from umbilical cord blood could also be a useful therapy in perinatal hypoxia-induced brain injury.
